Support Line: 0800 002 9002
General Enquiries: 01223 870008
Donate

News Archive

Nivolumab

Cabo + nivo & ipi delays kidney cancer progression

Cabo + nivo & ipi delays kidney cancer progression

Cabozantinib| Ipilimumab| Nivolumab
Adding cabozantinib (Cabometyx) to nivolumab (Opdivo) and ipilimumab (Yervoy) improved progression-free survival ...
Kidney Cancer UK represents patients at NICE nivo+ipi appraisal

Kidney Cancer UK represents patients at NICE nivo+ipi appraisal

Ipilimumab| NICE| Nivolumab
On 3rd February 2022, NICE approve the use of nivolumab with ipilimumab as a first line treatment for kidney ...